StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Maybe NEWS MARCH 1st.......SZLS

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Feb 27, 2021 11:13am

109 Views

Post# 32678786

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Maybe NEWS MARCH 1st.......SZLS

Cbg. You've got mail

capebretongirl wrote:

RelevantStock wrote:

MarketMoney wrote:
I always had mistrust on company that release frequent news, I prefer less frequent but more pertinent news

Me too, however in the case of Stagezero there is certainly a good balance to achieve, and they've worked on that a little bit lately with the interviews, social media posts, etc.

Frequent social media shouting companies indeed attract the wrong crowd, and they tend to have a very unhealthy amount of shorters and day traders sticked to them. I am thinking of XSPA doing similar covid testing as Stagezero, so many shorters are parasites to that stock they could never have a breakout regardless of how good the news was (and frequent they were).

For the moment, my strongest wish is that they do not wait until the very last minute (like keeping us waiting on a Friday night until 9pm), or repeat the mess of the last earning reports (the re-revaluation of warrants). Hoping they will do everything in a very profesionnal fashion this time for real, and of course like others that they match our very high expectations.

There has been criticism about the lack of NRs promoting the introduction of Aristotle and I have certainly been in that camp as we discuss here what we think would be ideal for the company's marketing/commercialization efforts. However, the reality is there is still time for Tripp to get at least one good NR out prior to Aristotle and do this right. There are catalysts out there to assist our launch while augmenting our covid revenue potential - the US March 14 covid funding bill will be one along with Biden's stated objective of ending cancer - we know there will be lots of funding which will certainaly include cancer detection testing. Covid has placed additional wealth in the pockets of the fortunate due to their inability to spend over the past year - read: less restaurant meals, shopping, leisure activities savings etc. etc. so the average cancer detection client can afford to have themselves tested. Come for covid and stay for cancer is a perfect storm situation for Stage as we have benefitted from free advertising by spreading word of our name out there. I have to think that Tripp has learned valuable over promised lessons in the past and indeed his rhetoric over the past 6 months has been much more refrained and deliberate which has added to his more recent credibility - the expectation now is that he knows the value of credibility, he has mentioned in numerous public forms that Aristotle will be out in Q1 so it would be inexplicable that he would drop the ball to the extent of missing this timeline. In short, we should be all good here so lts get it rolling.